Responsible of Pharmacy portfolio consisting of erectile dysfunction drug Viagra, topical anti-fungal Dermotrosyd and anti-colic agent Sab Simplex. (Total Portfolio Volume $27 Million) As a life cycle management initiative, launched Viagra ODT (orally disintegrating tablet) in Nov 2013, earlier before the expected launch time of Q2-2014 and contributed to overall revenue of Pfizer Turkey by $500K. Received Pfizer Emerging Markets Primary Care 2013 Recognition Award: Excellence in demonstrating optimized collaboration for the first Viagra ODT launch in EM. Designed and executed Pfizer National Pharmacy Academy as the major added-value program, which was awarded by Turkish Time magazine as fifth best-practice within non-marketing projects from all and the only one from pharma industry. Actively participated in Retail Team Project, a global initiative aimed at dividing local sales teams into two seperate divisions: One for physicians and other for pharmacies. Successfully implemented AVR (Availability, Visibility, Recommendation) marketing strategies and optimized trade channel campaign terms, increasing net revenues by as much as 45% and decreasing wholesaler stock levels by 40%.

Responsible of Gram(-) hospital antibiotics portfolio (Tazocin, Sulperazon and Cefobid) after acquisition of Wyeth. (Total Portfolio Volume $23 Million) Successfully integrated legacy-Wyeth product Tazocin to portfolio, relaunched the product and achieved 49% growth in the first year; being the largest contributor to overall Pfizer Turkey sales in absolute value (+$6 Million). Honored with Pfizer Emerging Markets Established Products 2010 Performance Award: "Revitalizing Tazocin Brand to Deliver Results" Rewarded by upper management for 2011 portfolio business plan; in which all strategical, tactical, medical, financial and regulatory details were thoroughly included. Invited to Pfizer Anti-Infectives Global Marketing Seminar and presented successful positioning of products without cannibalization as well as differentiation from generics. Demonstrated exceptional ability to manage and control the marketing budgets of all brands in Anti-Infectives Portfolio, summing up to $3 Million.

Responsible of primary care/acute portfolio consisting of oral antibiotic Duocid, topical anti-fungal Dermotrosyd and non-steroidal anti-inflammatory drug Ansaid. Involved in FF restructuring process and proposed transfer of Duocid to another team. Upon approval; relaunched the product with easier and self-explanatory concept, accomplishing smooth inclusion in the portfolio of the new team. Designed and implemented Key Bricks Analysis Program for reps. Monitored and analyzed daily/weekly/monthly sales to update field force on performance and provide necessary feedback on effective allocation of local sales budgets. Conducted periodical F2F market researches in order to measure brand awareness, to understand physicians' Rx choices and to monitor competition.

Started my career at Pfizer in Business Development Department, as a project manager in Management Leadership Development Program for fresh graduates. Gained experience at financials of products and P&L data; analyzed out-licenced products for margin revision and prepared quarterly management update reports. Evaluated the potential of infantile colic market, by combining IMS data and competitor intelligence, and initiated the registration of Sab Simplex in Turkish market.